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1. Introduction 
There is increasing evidence that infection with HIV may be associated with a 
hypercoagulate state. 
The incidence of thrombotic events in Human Immunodeficiency Virus (HIV)-infected 
patients is rising as suggested in recent retrospective cohort studies (1%- 2%, which is 10 times 
that expected among people without HIV) [1], but the underlying etiology remains uncertain. 
2. Procoagulant mechanisms underlying HIV infection 
Several mechanisms associated with HIV infection that may lead to predispose to a 
hypercoagulate state, in the absence of classic thrombophilic risk factors [2], are emerging.  
More than one “hit” seems to be involved [3]: 
2.1. Host risk factors 
2.1.1. Age 
HIV-infected patients are older than their chronological age, experiencing the so-called 
“premature aging ”, with persistent immunological defects and inflammation, even after 
years of treatment mediated viral suppression (similar to those seen in normal ageing, but 
they occur at an earlier age than normal): low CD4: CD8 ratio, low naïve: memory cell ratio 
and reduced responsiveness to vaccines. In addition, longevity and life expectancy is 
increasing due to effective antiretroviral therapy (ART), making HIV infection a chronic 
disorder. 
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In a Nederland cohort [4] of 109 patients with HIV, the annual incidences of venous and 
arterial thrombosis were 5- to 16-fold higher and 2- to 8-fold higher, respectively, than in the 
healthy population. The median age at the onset of venous thrombosis was 45 years, 17 
years earlier than the median age of onset for venous thrombosis in non-HIV- infected 
patients; and the median age for arterial thrombosis onset was 53 years, a decade earlier 
than that documented in the Framingham study.  
2.1.2. Hypercoagulate state - Primary prothrombotic abnormalities boosted by direct effect 
of HIV 
• Protein S (PS) deficiency (27-76%): decreased synthesis by the endothelial cells, 
hepatocytes and megakariocytes injured in HIV infection; antibodies to PS and low 
levels of circulating free antigen; tumor necrosis-factor alpha (TNF α) can lower the 
levels of active protein S, down-regulating the protein S synthesis in the endothelial 
cells; and loss of protein S in urine in HIV-related nephropathy [5]. 
• Protein C (PC) deficiency (0-14%): altered synthesis and metabolism of PC, as well as 
low-grade disseminated intravascular coagulation (DIC) with consumptive 
coagulopathy, in the setting of HIV infection with severe immunosuppression [5]. 
• Presence of Factor V Leiden (activated protein C resistance) [6]. 
• Antithrombin deficiency: decreased protein synthesis (liver diseases and malnutrition), 
protein-losing nephropathies or enteropathies, consumptive states (malignancy, 
surgery, DIC).  
• Antiphospholipid antibodies: Anticardiolipin antibodies (aCL) and lupus anticoagulant 
(LA) have been reported in HIV-infected patients with a prevalence ranging from 7 to 
94% and 0 to 72%, respectively. They have been implicated with antiphospholipid 
syndrome features (mainly avascular bone and cutaneous necrosis) or playing a limited 
role beside the multifactorial origin of HIV-related thrombosis [7]. HIV infection 
induces destruction of CD4 lymphocytes, which leads to polyclonal stimulation of B 
cells and hypergammaglobulinemia, resulting in antibodies against damaged 
endothelial cells (phospholipids exposed) and inhibition of protein S synthesis [5]. It is 
thought that LA activity in these patients might be an epiphenomenon secondary to 
chronic immune stimulation in HIV infection and no pathogenic correlation has been 
found with thromboses. 
• Tissue Factor (TF): TF expression on circulating monocytes has been postulated in the 
setting of driving immune activation by translocation of microbial products through the 
damaged gut. In addition, HIV- associated gp120 causes release of TF via activation of 
arterial smooth muscle cells [2]. 
• Microparticles (MP): The MP are generated from endothelial cells, platelets and 
apoptotic CD4 lymphocytes. 
• HIV-associated autoimmune haemolytic anemia has been related with an increased risk 
of thromboembolism during the acute phase of hemolysis [5]. 
• Homocysteine: Mild to moderate hyperhomocysteinemia (11-29%), related to a 
homozygous C677T mutation of the methylenetetrahydrofolate reductase gene [8], 
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especially in the setting of ART. It is not sufficient alone to cause thrombosis, but it 
may add an additional risk among patients with other risk factors for venous  
clots.  
• Endothelial dysfunction: A dysfunctional venous endothelium, induced by HIV, may 
express heparin cofactor II deficiency and increased amounts of P-selectin, von 
Willebrand factor, TF, plasminogen activator inhibitor-1 and factor V, all of which may 
promote blood clotting. Biomarkers of endothelial dysfunction [9] (P-selectin, D-dimer 
and hyaluronic acid), coagulation, and tissue fibrosis may help identify HIV-infected 
patients at elevated risk of venous thromboembolism (VTE). Other endothelial 
dysfunction biomarker is asymmetric dimethylarginine (ADMA), a competitive 
inhibitor for endothelial nitric oxide synthase (eNOS) which seems to be related to an 
increased immune activation pathways in HIV-1 infection [10]. 
In addition, intravenous drug use (IDU) can induce endothelial injury [11]. From a 
Danish HIV cohort [12], the 5-year risk of VTE was 8.0% [95% confidence interval (CI) 
5.78-10.74%] in IDU HIV-infected patients, 1.5% (95% CI 1.14-1.95%) in non-IDU HIV-
infected patients and 0.3% (95% CI 0.29-0.41%) in the population comparison cohort. 
In non-IDU HIV-infected patients, adjusted incidence rate ratios (IRRs) for 
unprovoked and provoked VTE were 3.42 (95% CI 2.58-4.54) and 5.51 (95% CI 3.29-
9.23), respectively, compared with the population comparison cohort. In IDU HIV-
infected patients, the adjusted IRRs were 12.66 (95% CI 6.03-26.59) for unprovoked 
VTE and 9.38 (95% CI 1.61-54.50) for provoked VTE. Low CD4 cell count had a minor 
impact on these risk estimates, while ART increased the overall risk (IRR 1.93; 95% CI 
1.00-3.72). 
• High density lipoprotein (HDL). A prospective study from South Africa [13] 
compared thrombotic profiles of 30 HIV-positive and 30 HIV-negative patients with 
acute coronary syndrome (ACS). Patients with HIV were younger; and besides 
smoking (73% vs 33%) and low HDL (0.8 ± 0.3 vs 1.1 ± 0.4), they had fewer traditional 
risk factors. Thrombophilia was more common in HIV-positive patients with lower 
protein C (PC; 82 ± 22 vs 108 ± 20) and higher factor VIII levels (201 ± 87 vs 136 ± 45). 
Patients with HIV had higher frequencies of aCL 47% vs 10%) and antiprothrombin 
antibodies (87% vs 21%). 
In addition to promoting cholesterol efflux from lipid-filled macrophages (foam cells) 
and reverse cholesterol transport, HDL protects low density lipoprotein (LDL) from 
oxidation and decreases expression of adhesion molecules on endothelial cells 
(including E-selectin and sICAM-1). HDL also improves endothelial function via 
stimulation of nitric oxide synthase activity, increases prostacyclin production by 
endothelial cells and inhibits endothelial TF expression, all of which enhance 
endothelium-dependent vasodilation and down-regulate thrombotic pathways. In this 
way, HDL possesses anti-inflammatory and antithrombotic properties. A cross-
sectional study [14] was designed to assess large and small high density lipoprotein 
particle (HDLp) concentrations in persons with untreated HIV infection. Lower small 
HDLp (primarily responsible for HDL’s anti-inflammatory properties and inhibition of 
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endothelial activation) concentrations and higher IL-6, sICAM-1 and D-dimer levels 
were found. The relationship of these markers to HIV-mediated atherosclerotic risk 
requires further study. The Strategies for Management of AntiRetroviral Therapy 
(SMART) trial demonstrated a 60% increased relative risk for cardiovascular disease 
(CVD) with a strategy of CD4+ cell count–guided interruption of ART, and adverse 
changes in HDL after stopping ART may explain some of the excess CVD risk. IL-6 and 
D-dimer levels increased after discontinuation of ART, and this was associated with 
increases in HIV RNA levels. In addition, baseline HDLp, but not low density 
lipoprotein particle (LDLp), predicted CVD risk in SMART. 
2.2. HIV disease state 
2.2.1. CD4 cell count 
CD4 cell count at the time of the thrombotic event, is the strongest predictor in some 
multivariate models. Protein C and protein S deficiencies [5] and increased von 
Willebrand factor and fibrinogen concentrations [4], have been correlated with 
immunossuppresion, evidenced by reduced CD4 cell counts. Although the frequency of 
thrombosis is higher in the presence of lower CD4, there are reports of thrombosis 
occurring with higher CD4 [15].  
2.2.2. Viral load 
High HIV RNA level is predictive of progression of HIV infection and higher risk of 
thrombosis. 
The frequencies of thrombophilic abnormalities (described above), increases with the progression to 
AIDS [2]. 
2.3. Comorbidities - Secondary prothrombotic abnormalities 
2.3.1. Infections 
A link between infection and thrombosis via endothelial activation [2] has been suggested, 
through up-regulation of some cytokines (the same ones that activate the coagulation 
system and appear during HIV infection), such as TNFα, IL-1, IL-6, factor VIII and 
fibrinogen, as well as down-regulation of fibrinolytic proteins, protein C (consumption as an 
antiinflammatory mediator) and free protein S concentrations. Deficiency of free protein S 
appears during an acute inflammatory process, such as opportunistic infections: C4b 
binding protein is increased up to 400% of its typical concentration [4] and binds free 
protein S, which is the active component as anticoagulant [5]. 
HIV-associated infections, including syphilis, Pneumocystis jiroveci, Mycobacterium 
tuberculosis and avium intracellulare [3] and hepatitis C [5], have been related to the 
induction of antiphospholipid antibodies (molecular mimicry between infectious agent 
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and beta2-glycoprotein I). Furthermore, cytomegalovirus induces thrombotic events via 
endo- thelial damage [5]. In a cross-sectional study [16] of 104 consecutive HIV- infected 
patients, active cytomegalovirus infection (defined as patients who had anti - 
cytomegalovirus antibody levels above the 75th percentile, > 209IU/ml), was associated 
with hypercoagulability independently of stage of HIV disease. It was observed higher 
levels of anticoagulant factors (antithrombin and total protein S levels) and higher 
procoagulant factors (factor VIII and fibrinogen levels), with a balance shifted to a 
procoagu- lant state. The majority of thrombosis have been associated with gastroin- 
testinal-related disease [3]. 
2.3.2. HIV-associated malignancy 
Kaposi´s sarcoma and non-Hodgkin lymphoma (B cell), via abnormalities of lymphatic flow 
and stasis; and anal and cervical carcinoma, via production of procoagulants, invasion of 
vascular space or secretion of vascular permeability factors from tumor cells [5]. 
2.4. Hospitalization 
Hospitalization in the past 3 months, was the risk factor more strongly associated with 
thrombosis in patients with HIV/AIDS, in a case-control study by Ahonkhai et al. [1]. 
2.5. Therapy 
- Protease Inhibitors (PI), in highly active ART (HAART), above all indinavir and 
saquinavir, are thought to interfere with hepatic metabolism, specifically cytochrome 
P450, and regulation of thrombotic proteins: increasing of the expression of CD36, 
receptor for oxidized LDL, inducing, in addition, increased absorption of cholesterol 
[2]. 
- HIV-positive individuals with lipodistrophy and fat redistribution induced by ART, 
may be at increased risk for developing an abnormal coagulation profile, such as 
increased fibrinogen, D-dimer, plasminogen activator inhibitor-1 or protein S 
deficiency.  
- Some authors recommend that clinicians must remain aware about the possibility of the 
occurrence of a thromboembolic event, especially during [17] the first few months after 
introduction of the ART.  
- However, other authors [18] have observed that ART or PI therapy does not appear to 
play a significant role in the occurrence of thrombotic events; advanced HIV disease is 
the most relevant risk factor for development of thromboses, possibly due to an 
increased inflammatory state or the presence of concurrent comorbidities such as 
infections.  
The Nederland cohort of 109 patients with HIV, previously referred above [4], showed 
that ART may improve thrombophilic abnormalities and lead to a decreased risk of 
venous and arterial thrombosis. 
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In other study [19], the incidence of VTE in patients with HIV in the post - protease 
inhibitor era (after 1996) was higher than in HIV patients before 1996. However, the 
higher incidence since 1996 is small, probably not clinically significant, and not 
necessarily because of protease inhibitors. 
Moreover, another study [20] analyzed levels of von Willebrand factor, D-dimer and 
factor VIII, in 160 HIV-infected and homosexual patients with a median age of 46 years, 
of whom 92% were male, 70% using ART, 74% Caucasian, 11% African American, 9% 
Hispanic, and 6% Asian. Significant lower levels of these parameters were observed in 
HIV-infected patients on ART compared to patients not on ART. Significant lower 
levels of protein C and free protein S, and increased activated protein C sensitivity ratio 
(APCsr) were found in the HIV-infected patients not on ART. However, although the 
prevalence of coagulation abnormalities was lower in HIV- infected patients using ART, a 
considerable proportion of HIV - infected patients on ART showed endothelial cell activation and 
increased APCsr, suggestive of a persistent procoagulant state. 
Immune depletion contributes to HIV – related inflammation, and ADMA 
concentrations decrease in patients with HIV infection under ART, slowing down 
endothelial activation. However, ADMA levels (or changes) did not consistently 
correlate with HIV RNA levels (or changes) [21]. 
Otherwise, some drugs from ART show more favourable profile related to decrease 
immune activation. Switching from ritonavir - boosted protease inhibitors to 
raltegravir (integrase inhibitor), appeared to de- crease biomarkers of inflammation 
(high sensitivity C reactive protein, osteoprotegerin, IL-6, TNFα, insulin and D-
dimer) [22]. 
- Megestrol acetate (progestational agent), used widely to stimulate appetite and weight 
gain in patients with AIDS-related anorexia and/or cachexia, could increase risk of VTE 
[3]. 
The data referred above, support the hypothesis that HIV-infected individuals are more 
likely to have clinically detected thromboembolic disease as opposed to non-HIV-infected 
individuals. One study performed by Malek et al. [23] revealed up to a 43% increase in 
developing a pulmonary embolism (PE), 10% increase in developing a deep venous 
thrombosis (DVT), and 40% increase in developing PE or DVT, in an HIV-infected 
individual over the 9-year study period. This increase differed by age group, with age group 
21 to 50 years having the highest odds for PE among HIV+ individuals (OR, 1.58; 95% CI, 
1.54-1.63). 
Also, other study by Kiser et al. [24], showed patients with HIV had higher rate of VTE, 
being younger than 50 years (3.31% vs 0.53% in age-matched healthy controls, p < 0.0001), 
had a CD4(+) cell count less than 200 cells/mm³, or a diagnosis of acquired 
immunodeficiency syndrome. 
Anyway, many authors propose the need to perform long-term, prospective studies 
assessing the factors associated with thrombotic events in patients with HIV. 
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3. Case reports 
[25] In a previous published letter, we described 9 patients with HIV infection and 
thrombotic event, defined as thrombosis involving an artery or a deep or splanchnic vein. 
Here, we included 2 patients more as follows. 
All of them were heterosexual patients, and one of them was an intravenous drug user. 
Median age was 38 years (range, 35-58 years). Seven of them were male. Only one patient 
had a family history of thrombosis (stroke). Four patients were coinfected with hepatitis C 
virus. The most frequent Centers for Disease Control and Prevention (CDC) HIV stage was 3 
[26]. There were neither AIDS-related malignancies or autoimmune disorders nor 
concurrent opportunistic infections at the time of the thrombotic event. Six patients were on 
ART, and only two patients were undergoing protease inhibitor therapy. Basic coagulation 
assays were unremarkable and only one patient was evaluated for hypercoagulate state and 
was found to have low protein C and S values. 
- Misdiagnosis of thromboembolism as a Pneumocystis jiroveci pneumonia (diagnosed by 
computed tomographic pulmonary angiogram) delayed anticoagulant treatment in a 
patient. Several months after this event, the same patient developed yugular vein 
thrombosis associated with a catheter placement. 
- Four patients had a diagnosis of lower extremity DVT, as confirmed by venous duplex 
ultrasonography. One of them had recurrent DVT, in the setting of progressive 
multifocal leukoencephalopathy. Another one, a young woman, developed a DVT in 
the setting of malabsorption syndrome by Giardia lamblia; she had been diagnosed with 
non-B HIV infection a few months before, and she showed high CD4 cell counts, high 
viral load, as well as increasing aCL antibodies and probably decreasing C protein and 
antithrombin-III (enteral loss); she was not receiving ART. 
- One male patient felt pain in the lower back since several weeks before admission, and 
his condition was diagnosed by abdominal computed tomography (CT), as inferior 
vena cava thrombosis (the patient had a congenital double inferior vena cava system). 
He was receiving interferon and ribavirin for the treatment of chronic hepatitis C. 
- A man was admitted to the hospital complaining of pain in the epigastric area. His 
condition was diagnosed by CT as alcoholic chronic pancreatitis and mesenteric vein 
thrombosis. 
- A woman was attended in the emergency unit because of massive hematemesis, and a 
portal vein thrombosis was documented by splanchnic angiography. A portocaval 
shunt was performed and the patient survived and went well. 
- Two patients died, and a suspicious diagnosis of pulmonary embolism was made on 
the basis of a clinical approach (pleuritic chest pain, cough and shortness of breath) in 
the setting of septic shock (an autopsy was not available) in one case, and by high-
probability ventilation/perfusion lung scanning, in another one. 
- A young man developed severe pulmonary hypertension secondary to recurrent 
pulmonary embolism, in the presence of aCL antibodies and high CD4 cells count, but 
high viral load, without ART. 
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4. Specific settings for thrombotic events 
4.1. Autoimmune background 
Autoimmune disturbances have emerged in the setting of immunological reconstitution and 
constant antigenic viral stimulation in HIV-infected patients. Different types of autoantibodies 
have been observed, including aCL, anti-Beta2-glycoprotein I and antiprothrombin antibodies 
[27]. Clinical challenges can arise when the two conditions coexist. 
Lupus anticoagulants were first described in AIDS and asymptomatic HIV-infected 
individuals (in whom they could be transient), by Bloom et al. in 1986. The association 
between aCL and HIV infection in men who have sex with men was reported in 1991. Falco 
et al., in 1993, found that, on the contrary to systemic lupus erythematosus (SLE), in the 
HIV-positive serum samples, reduced aCL binding capacity was evident if the cofactor 
(beta2-glycoprotein I) was added. Canoso et al. reported in 1997, aCL positivity in 
association with human T cell lymphotropic virus type 3 infection. 
The presence of SLE and HIV infection in the same individual is being increasingly 
reported, particularly in Africa and Asia. This coexistence has been associated with 
remissions or amelioration of SLE symptoms, with advancing HIV infection during pre-
Highly Active ART (HAART) era (before 1996 and introduction of protease inhibitors); or 
with flares in immune reconstitution, during effective HAART, through a cross-reactive 
mechanism between inflammatory factors and common nuclear antibodies.  
Overlapping features between SLE and HIV infection can include: arthralgias and 
arthritis, polyclonal B cell activation, antibodies against double-stranded DNA, anti-Smith 
antibodies, antiphospholipid antibodies and autoimmune haemolytic anemia with 
positive Coombs test; however, low complement has not been detected in HIV infection. 
In addition, patients with SLE without previous exposure to retroviral infection may 
express antibodies against retroviral proteins, including gag, env, nef and p24 of HIV-1, 
with false-positive results of ELISA and Western blot for detection of HIV. Some authors 
have suggested that these antibodies directed against HIV proteins may protect SLE 
subjects from exogenous infection.  
4.2. Immune reconstitution inflammatory syndrome (IRIS) 
When ART is started, a striking immune restoration inflammatory response can appear. In 
this setting, there could be a predisposition to thrombotic events, as in the case reported as 
follows [28]. A 26-year-old HIV-infected man who had started HAART a few months earlier, 
developed multiple linear nodules following the superficial veins in both legs. 
Histopathologic examination demonstrated a mostly septal panniculitis with features of 
superficial thrombophlebitis. Authors propose that superficial thrombophlebitis should be 
added to the list of clinical manifestations of this newly observed immune reconstitution 
disease. 
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4.3. Acute coronary artery disease and non-bacterial thrombotic endocarditis 
In addition to the issues referred above, protease inhibitors [29] have also been implicated in 
direct endothelial damage, which may be mediated by reduced nitric oxide production or 
release. The development of CVD risk factors such as insulin resistance, hyperlipidemia and 
fat redistribution syndrome, may exacerbate already existing underlying atherosclerotic risk 
in patients using these medications. However, necropsy studies de- monstrated premature 
CVD in HIV-infected patients even before the advent of protease inhibitors, indicating that other 
mechanisms might be involved independent of these drugs.  
Other authors could not demonstrate relation between a patient's human immunodeficiency 
virus status and valve thrombosis [30] or non-bacterial thrombotic endocarditis [31]. 
4.4. Non cirrhotic portal hypertension 
A multifactorial mechanism has been proposed to explain the pathogenesis of non-
cirrhotic portal hypertension (NCPH) in HIV-infected patients, and we have reviewed it 
and described two cases, in a previous published paper [32]: prothrombotic state, by HIV 
as a direct cause or through anti-protein S antibodies, leading to protein S deficiency; as 
well as didanosine, an ARTdrug, adenosine analogue, which has been postulated as an 
independent predictor of developing NCPH through cumulative dosing or idiosyncratic 
mechanisms. It results in an obliteration of the small portal venules and liver regenerative 
hyperplasia. Considering the data regarding prothrombotic abnormalities in HIV-infected 
patients, we wondered if patients with HIV and NCPH should be evaluated for 
hypercoagulate state. 
4.5. Pregnancy-puerperium 
Annual incidence of VTE within 3 months postpartum in a cohort of 41 consecutive HIV-
infected pregnant women [33], was 313 per 1000 person-years (95% CI, 65- 915). This risk is 
120-fold higher than in HIV-positive controls, whereas the risk is 157-fold higher compared 
to HIV-negative pregnant women. 
4.6. Other settings 
Thrombophilia might have a limited role in the development of osteonecrosis in HIV-
positive, according a case - control study [34], being only significantly associated with 
osteonecrosis: nadir of CD4(+) < 60 cells/microL and steroid use. 
5. Management 
Notably, the 2008 American College of Chest Physicians (ACCP) guidelines on antithrombotic 
and thrombolytic therapy, are silent regarding HIV-infected patients [35]. Anyway, the 
management of proven VTE should be the same as for the non HIV-patients [3]. 
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Some special issues must be considered: 
5.1. Antiretroviral therapy and warfarin drug interaction 
Interactions between warfarin and ART (non-nucleoside reverse transcriptase inhibitors-
NNRTIs and protease inhibitors-PIs), are through influence of ART on CYP2C9, the enzyme 
responsible for the metabolism of the more active S-enantiomer of warfarin [3]. Among the 
NNRTIs, induction of warfarin metabolism is likely with nevirapine. Inhibition of 
warfarin metabolism may occur with efavirenz o etravirine. Interactions involving 
ritonavir-boosted PIs are most frequent when warfarin is initiated in patients receiving 
concurrent efavirenz therapy [36]. International Normalized Ratio (INR) response should 
be used to guide warfarin dosage requirements; otherwise, low-molecular-weight heparin 
(LMWH) could be considered as a safer choice, although always keeping in mind that 
HIV infection may be an independent risk factor for the development of heparin-induced 
thrombocytopenia (HIT). 
5.2. Warfarin-induced skin necrosis (WISN) 
The presentation of WISN, a condition due to decrease protein C levels by warfarin, in HIV-
1 infected patients, is a novel clinical entity, reported recently [37]. Six cases of WISN 
occurred in 973 patients receiving warfarin therapy for venous thrombosis (0.62%, 95% CI 
0.25 - 1.37%) at a referral hospital in Cape Town, South Africa. All 6 cases occurred in HIV-1-
infected women (median age 30 years, range 27 - 42) with microbiologically confirmed 
tuberculosis (TB) and venous thrombosis. All were profoundly immunosuppressed (median 
CD4+ count at TB diagnosis 49 cells/microl, interquartile range 23 - 170). Of the 3 patients 
receiving combination ART, 2 had TB-IRIS. The occurrence of 6 WISN cases in a 40-month 
period may be attributed to: hypercoagulability secondary to HIV-1(above all if associated 
to decreased protein C levels) and TB, short concurrent heparin and warfarin therapy and 
high loading doses of warfarin. Active prevention and appropriate management of WISN 
are likely to improve the morbidity and mortality of this unusual condition. 
6. Questions and remarks arised from clinical practice [3, 25] 
- Should young patients (especially men) who develop thromboembolic events, in the 
absence of classic thrombophilic risk factors, be evaluated for HIV infection?  
- Given the overlapping features between SLE and HIV-infection, should be mandatory 
to rule out HIV infection in black South African patients with SLE (above all if they are 
not females of childbearing age), who present an unsatisfactory course?. 
- Should patients with HIV with severe immunosuppression be screened for 
prothrombotic abnormalities?  
- Venous thromboembolism can mimic opportunistic lung infection in patients with HIV; 
so, the former should be considered in differential diagnosis of lung diseases in this 
setting, above all when patients have unexplained dyspnea or hypoxemia. 
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- Should patients with HIV with low CD4 cell count receive prophylactic 
anticoagulation?  
- Appropriate prophylactic measures should be instituted, including low-molecular 
weight heparin on hospitalization and for high-risk HIV-infected outpatients. 
- HIV infection may be an independent risk factor for the development of heparin-
induced thrombocytopenia (HIT). Should be considered any special caution regarding 
it? 
- Finally, considering the absence of specific recommendations or guidelines on 
antithrombotic and thrombolytic therapy directed to VIH-infected patients, are 
traditional screening methods and management strategies applicable in HIV? 
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